Getting Mounjaro or Wegovy on the NHS: UK access explained

Understand the three decisions involved

MHRA authorisation defines the uses for which a medicine is licensed. NICE then evaluates whether NHS use is a good use of resources for specified groups. Local services organise assessment and treatment within the applicable funding arrangements. Meeting the licence criteria therefore does not automatically create an NHS prescription entitlement through your GP.

If you live in Scotland, Wales or Northern Ireland, ask about your nation's and local area's current pathway. The England thresholds below should not be presented as universal UK rules. If a service cannot offer treatment, ask which criterion or access arrangement applies and what other support is available.

What the current England pathway says

NICE recommends tirzepatide for adults with an initial BMI of at least 35 and at least one weight-related condition, with lower thresholds for specified ethnic backgrounds. NHS England's primary-care rollout is narrower. Its April 2026 guidance includes the original group with BMI at least 40 and four qualifying conditions, plus a 2026/27 group with BMI 35–39.9 and four qualifying conditions. The five qualifying conditions are hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease and type 2 diabetes.

Specialist access and local implementation need checking. For injectable semaglutide, NICE's weight-management recommendation uses specialist services and a maximum two-year treatment period. Do not assume this recommendation automatically covers the newly authorised tablets.

Why a specialist referral and a GP prescription can differ

A specialist weight-management service brings together different kinds of support, which may include medical, dietary and psychological care. Referral is an assessment route; it does not guarantee that a particular medicine will be prescribed. Ask what the service offers and what information is needed with a referral.

For injectable semaglutide, the NICE recommendation includes at least one weight-related condition with a BMI of at least 35, or BMI 30–34.9 when the criteria for specialist referral are met. Lower thresholds usually apply to specified ethnic backgrounds. Tirzepatide has a separate recommendation and phased primary-care access. A statement that somebody qualifies for one pathway therefore may not establish access through another. Your local service should explain the relevant distinction.

Make the appointment useful even if access is limited

Take a list of diagnosed conditions, current medicines and previous weight-management support. Explain what you want help with now, such as mobility, sleep or blood-sugar management. You can ask: ‘Which local pathway applies to me?’, ‘Is a referral appropriate?’ and ‘What support can I access while waiting?’

Ask the clinician to explain any ethnicity-related BMI adjustment rather than trying to decide eligibility from a calculator alone. If you are already paying privately, tell them. A move to NHS care needs an agreed handover; a private prescription does not guarantee NHS continuation. Keep your current prescriber involved while the next step is being clarified.

Prepare a short record of your previous support

Write down what you have tried, what helped and what made it difficult to continue. Include NHS programmes, dietetic advice, previous medicines and support you paid for yourself. There is no need to turn this into a case for proving that you deserve help. It gives the clinician a clearer picture of what could be useful next.

Bring dates where you know them and say when you are unsure. If you previously stopped a medicine, explain why and whether there was a suspected reaction. Mention accessibility needs, language support or appointment times you cannot manage. Ask whether advice can be provided in writing so you can consider the options after the appointment.

Ask for a plan while access is being clarified

A waiting list or a decision that you do not meet current funded criteria can leave you unsure what to do next. Ask what is available now: a local weight-management programme, help with a related condition, activity support or a dietitian where appropriate. Ask whether there is a review route if your health or the local policy changes.

If considering private treatment while waiting, check its ongoing affordability and discuss it with the clinician responsible for your other care. Do not assume NHS treatment will take over at a particular date. Ask who will monitor you and how records will be shared. Request the current local policy or patient information page so you can distinguish a documented rule from an informal impression.